BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rath T, Hage L, Kügler M, Menendez Menendez K, Zachoval R, Naehrlich L, Schulz R, Roderfeld M, Roeb E. Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease. PLoS One. 2013;8:e58955. [PMID: 23516586 DOI: 10.1371/journal.pone.0058955] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Omran D, Zayed RA, Nabeel MM, Mobarak L, Zakaria Z, Farid A, Hassany M, Saif S, Mostafa M, Saad OK, Yosry A. Evaluating Diagnostic Accuracy of Noninvasive Tests in Assessment of Significant Liver Fibrosis in Chronic Hepatitis C Egyptian Patients. Viral Immunol 2018;31:315-20. [PMID: 29630460 DOI: 10.1089/vim.2017.0134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 van de Peppel IP, Bertolini A, Jonker JW, Bodewes FAJA, Verkade HJ. Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease. Curr Opin Pulm Med 2017;23:562-9. [PMID: 28837442 DOI: 10.1097/MCP.0000000000000428] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
3 Kwon YC, Sasaki R, Meyer K, Ray R. Hepatitis C Virus Core Protein Modulates Endoglin (CD105) Signaling Pathway for Liver Pathogenesis. J Virol. 2017;91. [PMID: 28794048 DOI: 10.1128/jvi.01235-17] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
4 Meurer SK, Alsamman M, Scholten D, Weiskirchen R. Endoglin in liver fibrogenesis: Bridging basic science and clinical practice. World J Biol Chem 2014; 5(2): 180-203 [PMID: 24921008 DOI: 10.4331/wjbc.v5.i2.180] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
5 Klotter V, Gunchick C, Siemers E, Rath T, Hudel H, Naehrlich L, Roderfeld M, Roeb E. Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study. PLoS One 2017;12:e0178784. [PMID: 28575039 DOI: 10.1371/journal.pone.0178784] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
6 Stonebraker JR, Ooi CY, Pace RG, Corvol H, Knowles MR, Durie PR, Ling SC. Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. Clin Gastroenterol Hepatol 2016;14:1207-1215.e3. [PMID: 27062904 DOI: 10.1016/j.cgh.2016.03.041] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 9.3] [Reference Citation Analysis]
7 Gonçalves Lda R, Campanhon IB, Domingues RR, Paes Leme AF, Soares da Silva MR. Comparative salivary proteome of hepatitis B- and C-infected patients. PLoS One 2014;9:e113683. [PMID: 25423034 DOI: 10.1371/journal.pone.0113683] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
8 Nicola T, Kabir FL, Coric T, Wall SB, Zhang W, James M, MacEwen M, Ren C, Halloran B, Ambalavanan N, Harris WT. CFTR dysfunction increases endoglin and TGF-β signaling in airway epithelia. Physiol Rep 2019;7:e13977. [PMID: 30806029 DOI: 10.14814/phy2.13977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Munck A, Languepin J, Debray D, Lamireau T, Abely M, Huet F, Maudinas R, Michaud L, Mas E. Management of pancreatic, gastrointestinal and liver complications in adult cystic fibrosis. Revue des Maladies Respiratoires 2015;32:566-85. [DOI: 10.1016/j.rmr.2014.12.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
10 Addy C, Downey DG, Elborn JS. Improvements in symptomatic treatment strategies for cystic fibrosis: delivering CF care in the 21st century. Expert Opinion on Orphan Drugs 2015;4:5-19. [DOI: 10.1517/21678707.2016.1107473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Staufer K, Halilbasic E, Trauner M, Kazemi-Shirazi L. Cystic fibrosis related liver disease--another black box in hepatology. Int J Mol Sci 2014;15:13529-49. [PMID: 25093717 DOI: 10.3390/ijms150813529] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
12 Calvopina DA, Chatfield MD, Weis A, Coleman MA, Fernandez-rojo MA, Noble C, Ramm LE, Leung DH, Lewindon PJ, Ramm GA. MicroRNA Sequencing Identifies a Serum MicroRNA Panel, Which Combined With Aspartate Aminotransferase to Platelet Ratio Index Can Detect and Monitor Liver Disease in Pediatric Cystic Fibrosis: Hepatology. Hepatology 2018;68:2301-16. [DOI: 10.1002/hep.30156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
13 Thavamani A, Salem I, Sferra TJ, Sankararaman S. Impact of Altered Gut Microbiota and Its Metabolites in Cystic Fibrosis. Metabolites 2021;11:123. [PMID: 33671639 DOI: 10.3390/metabo11020123] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rath T, Zwaschka L, Hage L, Kügler M, Menendez K, Naehrlich L, Schulz R, Roderfeld M, Roeb E. Identification of neutrophil activation markers as novel surrogate markers of CF lung disease. PLoS One 2014;9:e115847. [PMID: 25545245 DOI: 10.1371/journal.pone.0115847] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
15 Pawlak JB, Blobe GC. TGF-β superfamily co-receptors in cancer. Dev Dyn 2021. [PMID: 33797167 DOI: 10.1002/dvdy.338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Cañas T, Maciá A, Muñoz-Codoceo RA, Fontanilla T, González-Rios P, Miralles M, Gómez-Mardones G. Hepatic and Splenic Acoustic Radiation Force Impulse Shear Wave Velocity Elastography in Children with Liver Disease Associated with Cystic Fibrosis. Biomed Res Int 2015;2015:517369. [PMID: 26609528 DOI: 10.1155/2015/517369] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
17 Martonosi ÁR, Soós A, Rumbus Z, Hegyi P, Izsák V, Pázmány P, Imrei M, Váncsa S, Szakács Z, Párniczky A. Non-invasive Diagnostic Tests in Cystic Fibrosis-Related Liver Disease: A Diagnostic Test Accuracy Network Meta-Analysis. Front Med (Lausanne) 2021;8:598382. [PMID: 34386504 DOI: 10.3389/fmed.2021.598382] [Reference Citation Analysis]
18 Dolezelova E, Sa ICI, Prasnicka A, Hroch M, Hyspler R, Ticha A, Lastuvkova H, Cermanova J, Pericacho M, Visek J, Lasticova M, Micuda S, Nachtigal P. High soluble endoglin levels regulate cholesterol homeostasis and bile acids turnover in the liver of transgenic mice. Life Sci 2019;232:116643. [PMID: 31299237 DOI: 10.1016/j.lfs.2019.116643] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
19 Parisi GF, Di Dio G, Franzonello C, Gennaro A, Rotolo N, Lionetti E, Leonardi S. Liver disease in cystic fibrosis: an update. Hepat Mon. 2013;13:e11215. [PMID: 24171010 DOI: 10.5812/hepatmon.11215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
20 Gómez-Cardona EE, Hernández-Domínguez EE, Velarde-Salcedo AJ, Pacheco AB, Diaz-Gois A, De León-Rodríguez A, Barba de la Rosa AP. 2D-DIGE as a strategy to identify serum biomarkers in Mexican patients with Type-2 diabetes with different body mass index. Sci Rep 2017;7:46536. [PMID: 28425473 DOI: 10.1038/srep46536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
21 Woolfson JP, Schreiber RA, Raveendran S, Chilvers M, Barker C, Guttman OR. Role of transient elastography and APRI in the assessment of pediatric cystic fibrosis liver disease. CanLivJ 2021;4:23-32. [DOI: 10.3138/canlivj-2020-0008] [Reference Citation Analysis]
22 Borowitz D, Gelfond D. Intestinal complications of cystic fibrosis. Curr Opin Pulm Med 2013;19:676-80. [PMID: 24060981 DOI: 10.1097/MCP.0b013e3283659ef2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
23 Igreja Sá IC, Tripska K, Hroch M, Hyspler R, Ticha A, Lastuvkova H, Schreiberova J, Dolezelova E, Eissazadeh S, Vitverova B, Najmanova I, Vasinova M, Pericacho M, Micuda S, Nachtigal P. Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver. Int J Mol Sci 2020;21:E9021. [PMID: 33261044 DOI: 10.3390/ijms21239021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Han H. Derivative component analysis for mass spectral serum proteomic profiles. BMC Med Genomics 2014;7 Suppl 1:S5. [PMID: 25080317 DOI: 10.1186/1755-8794-7-S1-S5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]